Lexaria Bioscience Corp., a global innovator in drug delivery platforms, has expanded its intellectual property portfolio with five newly granted patents, including two specifically for diabetes treatment using GLP-1 drugs. The company, trading on Nasdaq under the symbol LEXX, announced the patent awards resulting from its ongoing research and development programs.
The new patents include two in Japan for hypertension treatments, one in Australia for epilepsy treatment, and two in Australia for diabetes treatment. According to CEO Richard Christopher, the diabetes-related patents are particularly significant given the international competition within the GLP-1 industry. "Our new patents related to diabetes treatments utilizing our proprietary technology in conjunction with already-approved GLP-1 drugs is a notable achievement," Christopher stated.
The hypertension patents (7823051 and 7823052) were issued in Japan on February 20, 2026, with terms ending April 25, 2043. These additions bring Lexaria's total patents in this family to six, including three previously granted in the United States and one in Europe. The epilepsy patent (2024205127) was issued in Australia on February 12, 2026, with a term ending February 20, 2044, adding to the company's existing portfolio of six U.S., one European Union, and four Australian patents in this category.
Most notably, the two Australian diabetes patents (2025205229 and 2024394427) were issued on February 12, 2026, with terms ending December 3, 2044. These represent the newest additions to Lexaria's patent families and build upon two previously granted U.S. patents in this area. The company's recent Phase 1b human study conducted in Australia provided support for demonstrating the capabilities of its DehydraTECH technology in combination with GLP-1 drugs.
Lexaria's expanding patent portfolio has significant implications for the pharmaceutical industry and patients worldwide. The company's DehydraTECH technology, which improves how drugs enter the bloodstream through oral delivery, has shown potential to increase bio-absorption, reduce side effects, and enhance drug delivery across the blood-brain barrier. With diabetes affecting millions globally and GLP-1 drugs becoming increasingly important in treatment protocols, Lexaria's patented approaches could potentially improve treatment efficacy and patient outcomes.
The company's research initiatives are dedicated to advancing commercial relationships while establishing valuable intellectual property in multiple jurisdictions. Lexaria operates a licensed in-house research laboratory and maintains a robust intellectual property portfolio with 65 patents granted and additional patents pending worldwide. For more information about the company's technology and research, visit https://www.lexariabioscience.com.
These patent developments come at a time when pharmaceutical innovation is increasingly focused on improving drug delivery mechanisms to enhance treatment effectiveness while minimizing side effects. Lexaria's continued expansion of its patent portfolio positions the company to potentially license its technology to larger pharmaceutical firms or develop its own enhanced drug formulations. The company expects to receive additional patent awards in the future and will continue reporting on intellectual property developments as they occur.
